Individual bioequivalence - New concepts in the statistical assessment of bioequivalence metrics

被引：64

作者：

Patnaik, RN

Lesko, LJ

Chen, ML

Wiliams, RL

Balch, A

Chan, K

Machado, S

Schuirmann, D

Hauck, W

Schall, R

机构：

[1] US FDA, CDER, OCPB, HFD 850, ROCKVILLE, MD 20852 USA

[2] US FDA, CDER, OFF GENER DRUGS, DIV BIOEQUIVALENCE, ROCKVILLE, MD 20852 USA

[3] US FDA, CDER, OFF CLIN PHARMACOL & BIOPHARMACEUT, ROCKVILLE, MD 20852 USA

[4] US FDA, CDER, OFF PHARMACEUT SCI, ROCKVILLE, MD 20852 USA

来源：

CLINICAL PHARMACOKINETICS | 1997年 / 33卷 / 01期

关键词：

D O I：

10.2165/00003088-199733010-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

页码：1 / 6

页数：6

共 23 条

[1] CONSIDERATION OF INDIVIDUAL BIOEQUIVALENCE [J].

ANDERSON, S ;

HAUCK, WW .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (03) :259-273

[2]

ANDERSON S, 1993, BIOPHARMACEUTICAL RE, V2, P1

[3]

ANDERSON S, 1995, DRUG INF J, V29, P961

[4]

Chinchilli V M, 1996, J Biopharm Stat, V6, P1, DOI 10.1080/10543409608835118

[5] THE SUBJECT-BY-FORMULATION INTERACTION AS A CRITERION OF INTERCHANGEABILITY OF DRUGS [J].

EKBOHM, G ;

MELANDER, H .

BIOMETRICS, 1989, 45 (04) :1249-1254

[6]

EKBOHM G, 1990, 14 SWED U AGR SCI

[7]

ENDRENYI L, 1994, INT J CLIN PHARM TH, V32, P497

[8]

ENDRENYI L, 1993, F I P PAPERBACK, P141

[9]

Endrenyi L, 1995, DRUG INF J, V29, P847

[10]

Endrenyi L, 1993, DRUG INF J, V27, P195, DOI [10.1177/009286159302700135, DOI 10.1177/009286159302700135]

← 1 2 3 →